...
首页> 外文期刊>Fitoterapia >Hibiscus sabdariffa L. in the treatment of hypertension and hyperlipidemia: a comprehensive review of animal and human studies.
【24h】

Hibiscus sabdariffa L. in the treatment of hypertension and hyperlipidemia: a comprehensive review of animal and human studies.

机译:木槿sabdariffa L.在高血压和高脂血症的治疗:动物和人类研究的全面回顾。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The effectiveness of Hibiscus sabdariffa L. (HS) in the treatment of risk factors associated with cardiovascular disease is assessed in this review by taking a comprehensive approach to interpreting the randomized clinical trial (RCT) results in the context of the available ethnomedical, phytochemical, pharmacological, and safety and toxicity information. HS decoctions and infusions of calyxes, and on occasion leaves, are used in at least 10 countries worldwide in the treatment of hypertension and hyperlipidemia with no reported adverse events or side effects. HS extracts have a low degree of toxicity with a LD50 ranging from 2,000 to over 5,000 mg/kg/day. There is no evidence of hepatic or renal toxicity as the result of HS extract consumption, except for possible adverse hepatic effects at high doses. There is evidence that HS acts as a diuretic, however in most cases the extract did not significantly influence electrolyte levels. Animal studies have consistently shown that consumption of HS extract reduces blood pressure in a dose dependent manner. In RCTs, the daily consumption of a tea or extract produced from HS calyxes significantly lowered systolic blood pressure (SBP) and diastolic blood pressure (DBP) in adults with pre to moderate essential hypertension and type 2 diabetes. In addition, HS tea was as effective at lowering blood pressure as the commonly used blood pressure medication Captropril, but less effective than Lisinopril. Total cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglycerides were lowered in the majority of normolipidemic, hyperlipidemic, and diabetic animal models, whereas high-density lipoprotein cholesterol (HDL-C) was generally not affected by the consumption of HS extract. Over half of the RCTs showed that daily consumption of HS tea or extracts had favorable influence on lipid profiles including reduced total cholesterol, LDL-C, triglycerides, as well as increased HDL-C. Anthocyanins found in abundance in HS calyxes are generally considered the phytochemicals responsible for the antihypertensive and hypocholesterolemic effects, however evidence has also been provided for the role of polyphenols and hibiscus acid. A number of potential mechanisms have been proposed to explain the hypotensive and anticholesterol effects, but the most common explanation is the antioxidant effects of the anthocyanins inhibition of LDL-C oxidation, which impedes atherosclerosis, an important cardiovascular risk factor. This comprehensive body of evidence suggests that extracts of HS are promising as a treatment of hypertension and hyperlipidemia, however more high quality animal and human studies informed by actual therapeutic practices are needed to provide recommendations for use that have the potential for widespread public health benefit.
机译:本综述通过在综合的人类学,植物化学,药物学,药物学,药物学,药物学,药物学,药物学和环境学等领域的背景下,采用综合方法来解释随机临床试验(RCT)结果,评估了芙蓉(HS)在治疗与心血管疾病相关的危险因素中的有效性。药理,安全性和毒性信息。世界上至少有10个国家/地区使用HS汤剂和花萼注射液,有时还注射叶,用于治疗高血压和高脂血症,但无不良反应或副作用的报道。 HS提取物的毒性较低,LD 50 的范围从2,000到超过5,000 mg / kg /天。除了高剂量可能产生的不良肝脏影响外,没有证据表明食用HS提取物会引起肝或肾毒性。有证据表明HS可以作为利尿剂,但是在大多数情况下,提取物并未显着影响电解质水平。动物研究一致表明,食用HS提取物可以剂量依赖性降低血压。在随机对照试验中,每天食用由HS花萼制成的茶或提取物可显着降低患有中重度高血压和2型糖尿病的成年人的收缩压(SBP)和舒张压(DBP)。此外,HS茶在降低血压方面与常用的降压药Captropril一样有效,但效果不如Lisinopril。在大多数降血脂,高脂血症和糖尿病动物模型中,总胆固醇,低密度脂蛋白胆固醇(LDL-C)和甘油三酸酯均降低,而高密度脂蛋白胆固醇(HDL-C)通常不受摄入量的影响HS提取物。超过一半的RCT显示,每天食用HS茶或提取物对脂质谱具有良好的影响,包括总胆固醇降低,LDL-C,甘油三酸酯以及HDL-C升高。在花萼中大量发现的花色素苷通常被认为是负责降压和降胆固醇作用的植物化学物质,但是也提供了多酚和木槿酸作用的证据。已经提出了许多可能的机制来解释降压和抗胆固醇作用,但是最常见的解释是花青素抑制LDL-C氧化的抗氧化作用,这阻止了重要的心血管危险因素动脉粥样硬化。这种全面的证据表明,HS提取物有望作为治疗高血压和高血脂症的方法,但是需要通过实际治疗方法获得的更高质量的动物和人体研究,以提供具有广泛公共卫生益处的使用建议。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号